Compile Data Set for Download or QSAR
Report error Found 127 Enz. Inhib. hit(s) with all data for entry = 1596
TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332524(US10196354, Example 36B | 4-(1-(2-chloro-6- (trifl...)
Affinity DataIC50: 1nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332431(US10196354, Example 1AA | 4-(1-(2- chloro-6- cyclo...)
Affinity DataIC50: 2nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332433(US10196354, Example 1AC | 4-(1-(2- chloro-6- cyclo...)
Affinity DataIC50: 2nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332523(US10196354, Example 36A | 4-(6-(azetidine-1-carbon...)
Affinity DataIC50: 2nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332432(US10196354, Example 1AB | 4-(1-(2- chloro-6- cyclo...)
Affinity DataIC50: 3nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332520(US10196354, Example 34A | 4-(1-(2-chloro-6-cyclobu...)
Affinity DataIC50: 3nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332522(US10196354, Example 35B | 4-(1-(2-chloro-6- (trifl...)
Affinity DataIC50: 3nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332430(US10196354, Example 1Z | 4-(4-chloro-1- (2-chloro-...)
Affinity DataIC50: 4nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332437(US10196354, Example 2C | 4-(1-(2-chloro- 6-(triflu...)
Affinity DataIC50: 4nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332482(US10196354, Example 21A | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332517(US10196354, Example 33B | 4-(1-(2-chloro-6- cyclop...)
Affinity DataIC50: 5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332518(US10196354, Example 33C | 4-(1-(2-chloro-6- cyclop...)
Affinity DataIC50: 5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332411(US10196354, Example 1C | 4-(1-(2-chloro-6-cyclopro...)
Affinity DataIC50: 6nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332511(US10196354, Example 30A | 4-(5-acetamido-1-(2-chlo...)
Affinity DataIC50: 6nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332434(US10196354, Example 1AD | 4-(1-(2- chloro-6- morph...)
Affinity DataIC50: 7nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332516(US10196354, Example 33A | 4-(1-(2-chloro-6-cyclopr...)
Affinity DataIC50: 8nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332519(US10196354, Example 33D | 4-(1-(2-chloro-6- cyclop...)
Affinity DataIC50: 8nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332521(US10196354, Example 35A | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 11nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332534(US10196354, Example 43A | 4-(1-(2-chloro-6-cyclope...)
Affinity DataIC50: 11nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332477(US10196354, Example 17A | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 12nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332510(US10196354, Example 29B | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 13nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332462(US10196354, Example 7D | 4-(1-(2-chloro-6- (triflu...)
Affinity DataIC50: 14nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332470(US10196354, Example 9B | 4-(1-(2-chloro- 6- (trifl...)
Affinity DataIC50: 14nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332436(US10196354, Example 2B | 4-(1-(2-chloro-6- (triflu...)
Affinity DataIC50: 15nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332484(US10196354, Example 21C | 4-(1-(2-chloro-6- (trifl...)
Affinity DataIC50: 15nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332426(US10196354, Example 1V | 4-(1-(2-chloro- 6-vinyl- ...)
Affinity DataIC50: 16nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332435(US10196354, Example 2A | 4-(1-(2-chloro-6-(trifluo...)
Affinity DataIC50: 16nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332535(US10196354, Example 44A | 4-(1-(2-chloro-6-cyclobu...)
Affinity DataIC50: 16nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332483(US10196354, Example 21B | 4-(1-(2-chloro-6- (trifl...)
Affinity DataIC50: 17nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332473(US10196354, Example 13A | 4-(6-(3-aminoprop-1-ynyl...)
Affinity DataIC50: 20nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332476(US10196354, Example 16A | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 21nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332456(US10196354, Example 6C | 4-(6-(2-carboxyethylamino...)
Affinity DataIC50: 22nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332443(US10196354, Example 4F | 4-(1-(2-chloro-6- (triflu...)
Affinity DataIC50: 23nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332478(US10196354, Example 18A | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 24nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332455(US10196354, Example 6B | 4-(1-(2-chloro-6-(trifluo...)
Affinity DataIC50: 25nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332428(US10196354, Example 1X | 4-(1-(6-chloro- 2,3-dihyd...)
Affinity DataIC50: 26nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332479(US10196354, Example 18B | 4-(6-(5-bromooxazol-2-yl...)
Affinity DataIC50: 26nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332514(US10196354, Example 32A | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 29nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332427(US10196354, Example 1W | 4-(1-(2-chloro- 6-(prop-1...)
Affinity DataIC50: 33nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332492(US10196354, Example 22H | 4-(6-[4- (aminomethyl) p...)
Affinity DataIC50: 37nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332490(US10196354, Example 22F | 4-[1-{[2-chloro- 6- (tri...)
Affinity DataIC50: 39nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332429(US10196354, Example 1Y | 4-(1-(2- (dimethyl- amino...)
Affinity DataIC50: 40nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332451(US10196354, Example 5F | 4-(6-acetamido- 1-(2-chlo...)
Affinity DataIC50: 48nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332471(US10196354, Example 11A | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 48nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332410(US10196354, Example 1B | 4-(1-(2-chloro-6-(trifluo...)
Affinity DataIC50: 49nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332409(US10196354, Example 1A | (E)-4-(1-(2-chloro-6-(pro...)
Affinity DataIC50: 52nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332507(US10196354, Example 27A | 4-(1-(2-chloro-6-(triflu...)
Affinity DataIC50: 53nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332419(US10196354, Example 1O | 4-{1-[(2-bromo- 3-methyl-...)
Affinity DataIC50: 54nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332468(US10196354, Example 8D | 4-(1-(2-chloro- 6-(triflu...)
Affinity DataIC50: 57nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM332420(US10196354, Example 1P | 4-[1-(2,3- dihydro-1H- in...)
Affinity DataIC50: 58nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/14/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 127 total ) | Next | Last >>
Jump to: